v3.25.4
Equity (Tables)
12 Months Ended
Dec. 31, 2025
Equity [abstract]  
Transactions related to treasury shares When treasury shares are delivered by the company upon exercise of options, the difference between the cost
and the cash received is recorded in retained earnings. When treasury shares are delivered by the company
upon vesting of restricted shares or performance shares (granted under the company’s share-based
compensation plans), the difference between the market price of the shares and the cost is recorded in
retained earnings, and the market price is recorded in the share-based compensation reserve.
Philips Group
Treasury share transactions and share-based compensation in millions of EUR
2025
2024
2023
Treasury shares
113
54
54
Re-issuance of treasury shares
(60)
(36)
(29)
Share-based compensation cost
141
96
88
Income tax
4
5
2
Share-based compensation reserve
85
65
61
Retained earnings
(39)
(18)
(24)
Total shareholders' equity
159
101
91
Outstanding number of shares The accompanying table shows the movements in the outstanding number of shares over the last three years.
Philips Group
Outstanding number of shares
2025
2024
2023
Balance as of January 1
925,009,074
906,403,156
881,480,527
Dividend distributed
22,980,748
30,860,582
39,334,938
Purchase of treasury shares
-
(13,718,391)
(15,964,445)
Delivery of treasury shares
3,299,111
1,463,727
1,552,136
Balance as of December 31
951,288,934
925,009,074
906,403,156
Transactions related to share-based compensation plans The accompanying table reflects transactions that took place in relation to former and current share-based
compensation plans:
Philips Group
Transactions related to share-based compensation plans
2025
2024
2023
Shares acquired
-
9,281,227
3,000,000
Average market price
N/A
EUR 21.88
EUR 41.59
Amount paid
N/A
EUR 203 million
EUR 125 million
Shares delivered
3,299,111
1,463,727
1,552,136
Average price (FIFO)
EUR 34.31
EUR 37.14
EUR 34.59
Cost of delivered shares
EUR 113 million
EUR 54 million
EUR 54 million
Total shares in treasury at year-end
11,631,198
14,930,310
7,112,810
Total cost
EUR 298 million
EUR 411 million
EUR 262 million
Transactions related to capital reduction Transactions that took place for capital reduction purposes:
Philips Group
Transactions related to capital reduction
2025
2024
2023
Shares acquired
-
4,437,164
12,964,445
Average market price
N/A
EUR 37.56
EUR 37.25
Amount paid
N/A
EUR 167 million
EUR 483 million
Cancellation of treasury shares (shares)
-
4,437,164
15,134,054
Cancellation of treasury shares (EUR)
N/A
EUR 167 million
EUR 566 million
Total shares in treasury at year-end
-
-
-
Total cost
-
-
-
Composition of net debt and group equity Philips Group
Composition of net debt and group equity in millions of EUR unless otherwise stated
2025
2024
2023
Long-term debt
6,934
7,113
7,035
Short-term debt
1,151
526
654
Total debt
8,084
7,639
7,689
Cash and cash equivalents
2,794
2,401
1,869
Net debt
5,290
5,238
5,820
Shareholders’ equity
10,957
12,006
12,028
Non-controlling interests
32
37
33
Group equity
10,990
12,043
12,061
Net debt : group equity ratio
32:68
30:70
33:67
Adjusted income from continuing operations attributable to shareholders The reconciliation of Adjusted income from continuing operations
attributable to shareholders to the most directly comparable IFRS measure, Net income, is included in the
accompanying table.
Philips Group
Adjusted income from continuing operations attributable to shareholders 1 in millions of EUR
2025
2024
2023
Net income
897
(698)
(463)
Discontinued operations, net of income taxes
4
(142)
10
Income from continuing operations
901
(840)
(454)
Income from continuing operations attributable to non-
controlling interests
(1)
(3)
(2)
Income from continuing operations attributable to
shareholders ¹
899
(843)
(456)
Adjustments for:
Amortization and impairment of acquired intangible assets
240
392
290
Impairment of goodwill
-
-
8
Restructuring costs and acquisition-related charges
260
326
381
Other items:
270
830
1,358
Respironics litigation provision
-
984
575
Respironics insurance income
-
(538)
-
Respironics consent decree charges
97
113
363
Respironics field-action running costs
112
133
224
Contract settlement gain
(27)
-
-
Quality actions
89
123
175
Provision for a legal matter
-
-
31
Investment re-measurement loss
-
-
23
Loss (gain) on divestment of business
-
-
(35)
Remaining items
(1)
16
2
Net finance income/expenses
28
23
18
Tax impact on adjusting items ²
(192)
(370)
(450)
Tax effect of derecognition of US deferred tax asset
-
941
-
Adjusted Income from continuing operations attributable
to shareholders 1
1,506
1,300
1,148
1Shareholders in this table refers to shareholders of Koninklijke Philips N.V.
2Includes deferred tax assets derecognized in the line below